# China NMPA Drug Inspection - Chengdu Yicheng Pharmaceutical Co., Ltd. - Eriocaulon

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/chengdu-yicheng-pharmaceutical-co-ltd/c1ad44fc-098f-4bfd-b0a4-796486a85495/
Source feed: China

> China NMPA drug inspection for Chengdu Yicheng Pharmaceutical Co., Ltd. published December 01, 2021. Drug: Eriocaulon. On December 1, 2021, the Sichuan Provincial Drug Administration announced that six batches of traditional Chinese medici

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Sichuan Provincial Drug Administration Regarding 6 Batches of Drugs That Failed to Meet Regulations
- Company Name: Chengdu Yicheng Pharmaceutical Co., Ltd.
- Publication Date: 2021-12-01
- Drug Name: Eriocaulon
- Inspection Finding: The non-compliant item is the property.
- Action Taken: Suspend sales and use, recall, conduct investigation and rectification, initiate investigation.
- Summary: On December 1, 2021, the Sichuan Provincial Drug Administration announced that six batches of traditional Chinese medicine products from six different companies failed to meet quality standards. The companies involved are Chengdu Yicheng Pharmaceutical Co., Ltd., Sichuan Tianzhi Traditional Chinese Medicine Co., Ltd., Chengdu Mingde Pharmaceutical Co., Ltd., Sichuan Tongzhengtang Traditional Chinese Medicine Pieces Co., Ltd., Liangshan Xinxin Traditional Chinese Medicine Pieces Co., Ltd., and Gansu Mingui Traditional Chinese Medicine Technology Co., Ltd. The inspections, conducted by several regional food and drug inspection institutes, identified various quality violations including improper appearance, excessive moisture, failed content determination, high ash levels, and excessive sulfur dioxide residues. These violations fall under the regulatory framework of the Drug Administration Law of the People's Republic of China. In response, the Sichuan Provincial Drug Administration has required the companies to take immediate risk control measures, including the suspension of sales and use, as well as the initiation of product recalls. The companies must also investigate the root causes of these failures and implement corrective actions. Furthermore, regulatory authorities will pursue investigations into the production and sale of these substandard drugs and ensure the results are publicly disclosed.

Company: https://www.globalkeysolutions.net/companies/chengdu-yicheng-pharmaceutical-co-ltd/4c8cf2b0-87f7-4381-8a7e-d8d41cefeef8/